Tyra Biosciences (TYRA)
Developer of oral FGFR-targeted medicines for urothelial cancers and achondroplasia.
Something off on this page? Send us feedback.
Develops oral FGFR-targeted medicines for urothelial cancers, achondroplasia, liver cancer, and bile-duct cancer using an in-house structure-guided discovery platform. Dabogratinib anchors a wholly owned clinical pipeline, and the pre-commercial business relies on external capital while candidates move through trials and regulatory review.
Develops oral small-molecule medicines around fibroblast growth factor receptor biology for targeted cancers and genetically defined conditions. Its SNÅP platform combines iterative co-crystal structures, cell assays, and animal models to design for selectivity and resistance coverage. Lead candidate dabogratinib is in mid-stage trials for low-grade upper-tract urothelial carcinoma, intermediate-risk non-muscle-invasive bladder cancer, and pediatric achondroplasia.
Earlier programs include TYRA-430, in an early-stage trial for FGF19-positive hepatocellular carcinoma, and TYRA-200, in an early-stage trial for treatment-resistant FGFR2-driven intrahepatic cholangiocarcinoma. Clinical trials extend across U.S. and international sites, while development is headquartered in Carlsbad. The pipeline is wholly owned, but no product is approved and no revenue has been generated; operations depend on clinical results, regulatory approvals, and external financing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Oppenheimer | Target | Target: $50 | Target: $40 |
| Sep 22, 2026 | H.C. Wainwright | Target | Target: $45 | Target: $29 |
| Sep 8, 2026 | Piper Sandler | Reiterate | Rating: —Target: $42 | Target: $56 |
| Aug 5, 2026 | Jefferies | Reiterate | Rating: —Target: — | Target: $42 |
| Apr 14, 2026 | Guggenheim | Target | Target: — | Target: $54 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $353.9M · Total debt $5.6M · Total assets $383.4M · Shareholders' equity $353.7M
- Revenue
- $0
- Operating income
- −$49.0M
- Net income
- −$45.6M
No dividends on record.
| Institutions | ≈ 115.93% | 69.18M shares | |
|---|---|---|---|
| 177 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.86% | 1.71M shares | |
| 9 holders · as of Sep 17, 2026 | |||
| Strategic holders | 29.64% | 17.69M shares | |
| 3 holders · as of May 15, 2026 | |||
| Adds to | 148.43% | ||
59.68M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 148.43%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 20.44% | 12.20M | as of Jun 30, 2026 |
Boxer Capital Management, LLCStrategicother: See remarks. | 18.26% | 10.90M | filed Oct 22, 2024 |
FMR LLCInstitution | 14.95% | 8.92M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 7.29% | 4.35M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 6.52% | 3.89M | filed May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | +9,078,529 | $0.0010 |
| Sep 9, 2026 | Rehan Verjee | director | +972 | $20.58 |
| Mar 25, 2026 | Gilla Kaplan | director | −14,295 | $36.97 |
| Feb 12, 2026 | Daniel Bensen | officer: Chief Discovery Officer | −8,000 | $32.87 |
| Jan 12, 2026 | Daniel Bensen | officer: Chief Discovery Officer | −8,000 | $28.52 |
- Johnson & Johnson
Only approved FGFR inhibitor for mUC; advancing intravesical erda in IR NMIBC
- BridgeBio Pharma
Oral FGFR3 inhibitor for achondroplasia; Phase 3 met primary endpoint Feb 2026
- BioMarin
Approved CNP analog Voxzogo for achondroplasia; advancing long-acting BMN 333
- Ascendis Pharma (ADR)
Weekly SC CNP therapy for pediatric achondroplasia; FDA-approved Feb 2026
- Incyte
Pioneer FGFR inhibitor maker with FDA-approved pemigatinib in FGFR2-driven CCA
- Eli Lilly
Global pharma with FGFR3-selective mUC inhibitor and approved HCC VEGFR2 mAb
- Relay Therapeutics
Originator of FGFR2-selective lirafugratinib, licensed to Elevar for CCA
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tyra Biosciences | $25.46 | −0.76% | $1.53B | — | — | — | — |
| Johnson & Johnson | $268.61 | −0.32% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| BridgeBio Pharma | $69.42 | +4.27% | $13.04B | — | — | 18.8 | +120.4% |
| BioMarin | $64.46 | +0.63% | $12.38B | 164.3 | 10.5 | 3.6 | +20.0% |
| Ascendis Pharma (ADR) | $236.98 | −0.26% | $14.76B | 18.1 | 33.8 | 12.2 | +108.2% |
| Incyte | $126.15 | +1.20% | $25.27B | 15.9 | 52.2 | 4.3 | +37.7% |
| Eli Lilly | $1,169.18 | +0.37% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Relay Therapeutics | $18.52 | +1.81% | $3.99B | — | — | 385.1 | −48.3% |
| Median | 31.2 | 28.6 | 12.2 | +37.7% |